Diskusjon TriggereNy! Porteføljer

NattoPharma (NATTO)

natto_ol
Investeringer: #<Tag:0x00007ff2958f2020>

#467

Sikkert lengere horisont enn 79 år gamle Karstein Gjersvik :slight_smile:


#468

Nå har spin off selskapet Kaydence Pharma fått hjemmeside

https://kaydencepharma.com


#469

Trad4
I går kl 20:57
289
Da er det innkalt til investorpresentasjon den 9.aug i Kaydence Pharma. Det blir spennende å se planen deres fremover!
Presented by CEO Dan Rosenbaum
Agenda:
• Business model
• IPR (Patent) strength
• Market potential
• The team / expertise
• Regulatory strategy
• Key elements of the integrated development plan
• Financials
• The plan for listing at The Oslo Stock Exchange
• Q&A


#470

INVITATION TO PRESENTATION OF FIRST HALF 2018 FINANCIAL RESULTS

NattoPharma will release its first half 2018 financial results on Wednesday 22nd
August 2018 at approximately 08:00 CET. The first half 2018 financial report
will be made available at www.nattopharma.com and at www.oslobors.no.

The same day, starting at 10:00 am, the company will host a webcast with a
presentation of the results, followed by an online Q&A session.

Please follow the below link to join the web-cast,

http://webtv.hegnar.no/presentation.php?webcastId=92032125

The presentation will be held by CEO Kjetil Ramsøy and SVP Global Sales &
Marketing Christopher Speed

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma

E-mail: [email protected]

Ekstern link: http://www.newsweb.no/index.jsp?messageId=457035

Nyheten er levert av OBI.

http://www.netfonds.no/quotes/release.php?id=20180814.OBI.20180814S26


#471

Hva tenker folk om rapport 22/8? Klarer de opprettholde tilveksten?


#472

Jeg tror de leverer som guidet, de hadde jo 4 av 6 måneder når de oppdaterte guidingen. :slight_smile:


#473

Er ikke godt insatt i selskapet, dukket opp i min screener Er Q4 enn one-off eller har de turn-around på gang? Hva har dem guidetet fremover?


#474

https://www.netfonds.no/quotes/release.php?id=20180509.OBI.20180509S80

image


#475

Trenden er veldig god, men du bør se på ebit. På resultatet er det en engangseffekt. Vi kan regne med break-even i år og i 2019 vil vi nok se et veldig bra resultat


#476

Innisdere kjøper vel også jevnt og trutt? Sitter du forsatt godt lastet her @holmes?


#477

Ja, jeg har ikke gjort noe. Bare de holder stø kurs med høy vekst bør det bli veldig god uttelling etterhvert.


#478

Her ser du samme oversikt med EBIT, nå vet vi at det i hvert fall blir sterk omsetningsvekst i H1.


#479

Kan noen forklare en rookie, hvorfor det er slik? Hva er forskjellen?


#480

NattoPharma er registrert på Oslo og Stockholm-børsen. Det er veldig få aksjer på Stockholm-børsen og den blir veldig lite tradet. Du kan ikke selge en “stockholm”-aksje på OAX og vice versa, så det er vanskelig å få til noe arbitrasje.


#481

NATTOPHARMA APPLY FOR DELISTING FROM NASDAQ FIRST NORTH

The Board of Directors of NattoPharma ASA has resolved to apply for delisting of
the company’s shares from Nasdaq First North.
Information about the last trading date on Nasdaq First North will be made
public well in advance through a press release from the company.

The reason for this decision of desired delisting is that the company is
primarily listed on Oslo Axess and due to low trading volumes on both Oslo Axess
and Nasdaq First North, the board wishes to consolidate all trading in one
marketplace with the aim of increasing the activity in the stock and thereby
give shareholders a better opportunity to buy and sell shares in the company.

The company has approx. 625 shareholders registered at Oslo Axess, and another
approx. 260 shareholders registered on Nasdaq First North. With the choice of
marketplace, there are therefore important reasons why the continuation of
trading on Oslo Axess is the most shareholder-friendly approach rather than a
delisting in Oslo and the continuation of primary listing on Nasdaq First North.
The Board therefore considers that it has fulfilled its obligation to safeguard
the interests of the company and all shareholders by ensuring that trading in
the stock will continue on Oslo Axess. The Board further considers that the
decision on possible delisting is not contrary to good practice in the Swedish
stock market. This is also supported by a statement from Aktiemarknadsnemden,
who has been consulted in the process to prepare for this application of
delisting.

The activity on Nasdaq First North during the period 1 January 2018 to 26 June
2018 is an average of 1.12 trades per trading day, with an average daily value
of SEK 17,500. Similarly, in the same period, average 5.8 trades with a daily
average value of NOK 76,200 have been conducted on Oslo Axess. The trading
volume of Nasdaq First North indicates that there is little general interest in
conducting trading through the marketplace and the board is of the opinion that
the activity does not support continued listing on Nasdaq First North as a
secondary trading venue for the company’s shares.

The Board believes that it may apply for delisting without first obtaining
support from all shareholders through a general meeting as the main weight of
the company’s shareholders is registered in Norway. In addition, over 45% of the
total number of shares registered in Sweden is owned by large shareholders who
are already registered with significant shares in Oslo Axess. These have
consented to delisting from Nasdaq First North. This means that of a total of
approx. 18.1 million shares registered in the company, then it is approx.
850,000 shares or approx. 4.7% of the share capital, which will be transferred
to Oslo Axess without giving specific consent.

The shareholders in NattoPharma whose shares are currently registered on Nasdaq
First North will still be able to trade their shares by transferring the shares
to “Norwegian” shares. Shareholders who own shares through trustees will be able
to continue to buy and sell shares through their trading channels at their
nominee banks in line with today’s solution. The disadvantages of the delisting
from Nasdaq First North are thus very limited for shareholders whose shares per
today is listed there.

NattoPharma has engaged Eminova Fondkommission AB to assist in the practical
management of transferring the shares currently listed at Nasdaq First North to
a trading account at Oslo Axess. For further information about how to proceed to
ensure the safe transfer of shares, please contact; Eminova Fondkommission AB by
phone on +46 08-68421100 or by email to [email protected]

As previously mentioned, NattoPharma ASA will continue its listing on Oslo Axess
and will also fulfill all requirements Oslo Børs / Oslo Axess proposes to
issuers of shares in the open marketplace. This will further safeguard the
interests of Swedish shareholders in continuous information about significant
events in NattoPharma ASA following the delisting from Nasdaq First North. Any
shareholder who wishes to receive ongoing information in connection with the
company’s messages to Oslo Axess may subscribe to automatic messages from the
company when such items are sent through the company’s news service.

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma

E-mail: [email protected]

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

This information is information that NattoPharma ASA (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was submitted
for publication through the agency of the contact person set out above at 8:00
am CET on August 22nd, 2018.

Ekstern link: http://www.newsweb.no/index.jsp?messageId=457749

Nyheten er levert av OBI.

http://www.netfonds.no/quotes/release.php?id=20180822.OBI.20180822S25


#482

NATTO: 2018 Half Year Earnings Release

Please find attached the Nattopharma Group 2018 Half Year Earnings Release.

Financial highlights for the First Half of 2018 are;

· Product revenue rose by 54,2% to NOK 47,2 million
· Gross Margin for the period was 41,7 %,
· Positive adjusted EBITDA of NOK 2,5 million

A presentation will be held via webcast by CEO Kjetil Ramsøy and SVP Global
Sales & Marketing Christopher Speed at 10 am CET, Wednesday 22nd August 2018,
followed by a Q&A session directly thereafter.

Please follow the below link to join the webcast;

http://webtv.hegnar.no/presentation.php?webcastId=92032125

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma

E-mail: [email protected]

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

This information is information that NattoPharma ASA (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was submitted
for publication through the agency of the contact person set out above at 8:00
am CET on August 22nd,

Ekstern link: http://www.newsweb.no/index.jsp?messageId=457751

Nyheten er levert av OBI.

http://www.netfonds.no/quotes/release.php?id=20180822.OBI.20180822S27


#483

Veldig bra vekst i hvert fall!

We see that the activity with our current and new customers is growing ahead of our previous guiding. In the
first half of 2018 we have a growth of 54% - outperforming our current guiding of an annual growth between
40% and 50% for the full year. Comparing revenue during the first half of the year to the same period in the
years from 2015 and forward, we have realized growth of more than 225%. On a rolling 12 months basis we
now have revenue of more than NOK 80 million.

image


#484

:face_with_raised_eyebrow:


#485

Hos hegnar redaksjonen er glasset alltid halvtomt når det gjelder Natto. Nå ligger selskapet nær break-even og leverer kraftig vekst, men det går jo an å vinkle det negativt når resultatet ligger såvidt i minus.


#486

Fin vekst, men kostnadene øker også betydelig. Det koster å øke omsetningen mye. TTT i Natto. Caset ligner litt på PHO synes jeg.

image